Rapport Therapeutics, Common Stock Market Value
| RAPP Stock | 24.00 1.16 5.08% |
| Symbol | Rapport |
Rapport Therapeutics, Company Valuation
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rapport Therapeutics,. If investors know Rapport will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rapport Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.72) |
The market value of Rapport Therapeutics, is measured differently than its book value, which is the value of Rapport that is recorded on the company's balance sheet. Investors also form their own opinion of Rapport Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Rapport Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rapport Therapeutics,'s market value can be influenced by many factors that don't directly affect Rapport Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rapport Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Rapport Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rapport Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Rapport Therapeutics, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Rapport Therapeutics,'s stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Rapport Therapeutics,.
| 12/14/2022 |
| 12/03/2024 |
If you would invest 0.00 in Rapport Therapeutics, on December 14, 2022 and sell it all today you would earn a total of 0.00 from holding Rapport Therapeutics, Common or generate 0.0% return on investment in Rapport Therapeutics, over 720 days. Rapport Therapeutics, is related to or competes with Cars, Amkor Technology, Wabash National, Marine Products, Usio, Modine Manufacturing, and CarsalesCom. Rapport Therapeutics, is entity of United States More
Rapport Therapeutics, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Rapport Therapeutics,'s stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Rapport Therapeutics, Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.18 | |||
| Information Ratio | 0.0572 | |||
| Maximum Drawdown | 23.48 | |||
| Value At Risk | (8.17) | |||
| Potential Upside | 10.61 |
Rapport Therapeutics, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rapport Therapeutics,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Rapport Therapeutics,'s standard deviation. In reality, there are many statistical measures that can use Rapport Therapeutics, historical prices to predict the future Rapport Therapeutics,'s volatility.| Risk Adjusted Performance | 0.0698 | |||
| Jensen Alpha | 0.1083 | |||
| Total Risk Alpha | (0.39) | |||
| Sortino Ratio | 0.0598 | |||
| Treynor Ratio | 0.1535 |
Rapport Therapeutics, Backtested Returns
Rapport Therapeutics, appears to be not too volatile, given 3 months investment horizon. Rapport Therapeutics, maintains Sharpe Ratio (i.e., Efficiency) of 0.0623, which implies the firm had a 0.0623% return per unit of risk over the last 3 months. We have found thirty technical indicators for Rapport Therapeutics,, which you can use to evaluate the volatility of the company. Please evaluate Rapport Therapeutics,'s Coefficient Of Variation of 1247.87, risk adjusted performance of 0.0698, and Semi Deviation of 4.57 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Rapport Therapeutics, holds a performance score of 4. The company holds a Beta of 2.76, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rapport Therapeutics, will likely underperform. Please check Rapport Therapeutics,'s skewness, and the relationship between the value at risk and day median price , to make a quick decision on whether Rapport Therapeutics,'s historical price patterns will revert.
Auto-correlation | 0.00 |
No correlation between past and present
Rapport Therapeutics, Common has no correlation between past and present. Overlapping area represents the amount of predictability between Rapport Therapeutics, time series from 14th of December 2022 to 9th of December 2023 and 9th of December 2023 to 3rd of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Rapport Therapeutics, price movement. The serial correlation of 0.0 indicates that just 0.0% of current Rapport Therapeutics, price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Rapport Therapeutics, lagged returns against current returns
Autocorrelation, which is Rapport Therapeutics, stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Rapport Therapeutics,'s stock expected returns. We can calculate the autocorrelation of Rapport Therapeutics, returns to help us make a trade decision. For example, suppose you find that Rapport Therapeutics, has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Rapport Therapeutics, regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Rapport Therapeutics, stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Rapport Therapeutics, stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Rapport Therapeutics, stock over time.
Current vs Lagged Prices |
| Timeline |
Rapport Therapeutics, Lagged Returns
When evaluating Rapport Therapeutics,'s market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Rapport Therapeutics, stock have on its future price. Rapport Therapeutics, autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Rapport Therapeutics, autocorrelation shows the relationship between Rapport Therapeutics, stock current value and its past values and can show if there is a momentum factor associated with investing in Rapport Therapeutics, Common.
Regressed Prices |
| Timeline |
Pair Trading with Rapport Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rapport Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rapport Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving against Rapport Stock
| 0.48 | FATE | Fate Therapeutics | PairCorr |
| 0.38 | VRCA | Verrica Pharmaceuticals | PairCorr |
| 0.35 | EPIX | ESSA Pharma Earnings Call This Week | PairCorr |
| 0.34 | A | Agilent Technologies | PairCorr |
| 0.33 | VRAX | Virax Biolabs Group | PairCorr |
The ability to find closely correlated positions to Rapport Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rapport Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rapport Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rapport Therapeutics, Common to buy it.
The correlation of Rapport Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rapport Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rapport Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rapport Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Rapport Stock Analysis
When running Rapport Therapeutics,'s price analysis, check to measure Rapport Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics, is operating at the current time. Most of Rapport Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics,'s price. Additionally, you may evaluate how the addition of Rapport Therapeutics, to your portfolios can decrease your overall portfolio volatility.